![]() |
市场调查报告书
商品编码
1697828
高内涵筛检市场:全球按产品/服务、应用、最终用户和地区划分 - 预测至 2030 年High Content Screening Market by Product & Services (Instrument (Cell Imaging, Analysis System), Consumables (Reagents & Assay Kits, Microplates), Software), Application (Drug Discovery & Development, Toxicology), End User - Global Forecast to 2030 |
全球高内涵筛检市场规模预计将从 2025 年的 15.2 亿美元成长到 2030 年的 21.9 亿美元,复合年增长率高达 7.5%。
由于高解析度成像、自动化和人工智慧 (AI) 驱动的资料分析的创新显着提高了 HCS 工作流程的效率和准确性,市场正在以显着的复合年增长率成长。具有高速萤光显微镜、共聚焦成像和即时活细胞分析功能的先进仪器可以更深入地了解细胞,对于药物发现、毒性筛检和疾病研究至关重要。
研究范围 | |
---|---|
调查年份 | 2023-2030 |
基准年 | 2024 |
预测期 | 2025-2030 |
对价单位 | 金额(美元) |
按细分市场 | 按产品/服务、按应用、按最终用户、按地区 |
目标区域 | 北美、欧洲、亚太地区、拉丁美洲、中东和非洲 |
根据产品/服务,高内涵筛检市场可细分为仪器、消耗品/配件、软体和服务。仪器部分进一步分为高内涵成像平台、细胞检测和分析系统以及细胞成像系统。製药和生物技术研究中对高通量筛检和多重分析的需求不断增长,加速了下一代 HCS 系统的采用。随着研究机构和商业实验室致力于提高生产力和效率,对尖端 HCS 设备的需求预计将推动市场大幅成长。
应用部分分为药物发现和开发、毒理学和基础研究。药物发现和开发应用可进一步分为筛检筛检和二次筛选、标靶识别和验证、化合物分析以及其他药物发现和开发应用。药物发现和开发占据了市场主导地位,因为人工智慧和自动化在药物发现工作流程中的整合进一步提高了HCS的效率,减少了与临床前研究相关的时间和成本。此外,监管机构非常重视早期毒性评估,使得HCS成为临床试验前药物安全性评估的首选工具。由于这些因素的综合作用,药物发现和开发应用占据了HCS市场的绝大部分份额。
根据最终用户,市场细分为製药和生物技术公司、学术和政府组织以及 CRO 和 CDMO。到 2024 年,製药和生物技术公司将主导这一领域。製药和生物技术公司在高内涵筛检(HCS) 市场中的高份额主要是由于 HCS 技术在药物发现和市场开发中的广泛应用。这些公司利用HCS进行高通量筛检、先导化合物优化和毒性评估,以加速药物开发过程,同时确保安全性和有效性。
市场依地区分为北美、欧洲、亚太、拉丁美洲及中东及非洲。 2024 年,北美占据了高内涵筛检市场的主导地位,预计在预测期内将继续占据主导地位。美国凭藉其主要学术研究机构和对生物技术的大量投资引领北美市场。该国对创新医学研究、个人化医疗保健和精准医疗的关注进一步巩固了其在市场上的领先地位。欧洲高内涵筛检市场正在稳步成长,这得益于不断增加的研发活动,尤其是在德国、英国和法国等国家。
本报告研究了全球高内涵筛检市场,并对市场按产品/服务、应用、最终用户和地理趋势进行了详细分析,并提供了参与市场的公司概况。
The global high content screening market is anticipated to reach USD 2.19 billion in 2030 from USD 1.52 billion in 2025, with a significant CAGR of 7.5%. The market is growing at a significant CAGR owing to the innovations in high-resolution imaging, automation, and artificial intelligence (AI)-powered data analysis, which have significantly enhanced the efficiency and accuracy of HCS workflows. Advanced instruments equipped with high-speed fluorescence microscopy, confocal imaging, and real-time live-cell analysis enable deeper cellular insights, making them essential for drug discovery, toxicity screening, and disease research.
Scope of the Report | |
---|---|
Years Considered for the Study | 2023-2030 |
Base Year | 2024 |
Forecast Period | 2025-2030 |
Units Considered | Value (USD) |
Segments | By Products & Service, Application and End User |
Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
"Instruments dominated the products & service segment"
Based on product & service, the high content screening market is divided into instruments, consumables & accessories, software, and services. The instrument segment is further divided into high content imaging platforms, cell detection and analysis systems, and cell imaging systems. The rising demand for high-throughput screening and multiplexed assays in pharmaceutical and biotechnology research has accelerated the adoption of next-generation HCS systems. As research institutions and commercial laboratories seek to improve productivity and efficiency, the demand for cutting-edge HCS instruments is expected to drive significant market growth.
"Drug discovery & development application segment is anticipated to grow at a great pace"
The application segment is divided into drug discovery & development applications, toxicology, and basic research. The drug discovery & development application segment is further divided into primary screening and secondary screening, target identification and validation, compound profiling, and other drug discovery & development applications. The drug discovery & development dominated the market owing to the integration of artificial intelligence and automation in drug discovery workflows further enhances the efficiency of HCS, reducing time and costs associated with preclinical research. Furthermore, regulatory bodies emphasize early toxicity assessment, making HCS a preferred choice for evaluating drug safety before clinical trials. These factors collectively contribute to the dominant market share of drug discovery and development applications in the HCS market.
"Pharmaceutical & Biotechnology Companies dominated the segment"
Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, academic & government institutes, and CROs & CDMOs. Pharmaceutical & biotechnology companies dominated the segment in 2024. The high share of pharmaceutical and biotechnology companies in the high content screening (HCS) market is primarily driven by their extensive use of HCS technologies in drug discovery and development. These companies rely on HCS for high-throughput screening, lead optimization, and toxicity assessment to accelerate the drug development process while ensuring safety and efficacy.
"North America: the largest share of the high content screening market"
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the high content screening market in 2024 and is estimated to continue dominance during the forecast period. US leads the North American market, driven by the presence of leading academic & research institutions, and significant investment in biotechnology. The country's focus on innovative medical research, personalized healthcare, and precision medicine further boosts its leadership in the market. European high content screening market is experiencing steady growth, supported by increasing research and development activities, especially in countries like Germany, the UK, and France.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the high content screening market.
The prominent players operating in the high content screening market are Danaher Corporation (US), Revvity, Inc. (US), BD (US), Carl Zeiss AG (Germany), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies Inc. (US), Corning Incorporated (US), Bio-Rad Laboratories Inc (US), Tecan Trading AG (Switzerland), Evident (Japan), Sysmex Corporation (Japan), Yokogawa Electric Corporation (Japan), Nikon Corporation (Japan), Sartorius AG (Germany), Promega Corporation (US), Creative Biolabs (US), Enzo Life Sciences (US), Stratedigm Inc. (US), Akoya Biosciences, Inc. (US), Sphere Fluidics (UK), Creative Biostructure (US), Creative Bioarray (US), Cell Signalling Technology (US), Standard Biotools (US), Araceli Biosciences (US), and among others.
High content screening market report is segmented based on products & services (instruments (high content imaging platforms, cell detection and analysis systems, and cell imaging systems), consumables & accessories (reagents & assay kits, microplates, and other consumables accessories), software, and services. Applications (drug discovery & development applications (primary screening and secondary screening, target identification and validation, compound profiling, and other drug discovery & development applications), toxicology, and basic research, end users (pharmaceutical & biotechnology companies, academic & government institutes, and CROs & CDMOs). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the high content screening market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the high content screening market.
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the high content screening and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.